GlassScriptPhysician profile
Prasanthi Kandula
NPI 1225458185
$5,539.36
in general payments reported to CMS, 2019-2025
37 companies · $998 in 2025
The $998 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $533 · 2021: $827 · 2022: $571 · 2023: $934 · 2024: $494 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.27 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.76 | 2019-2025 | |
| Janssen Biotech, INC. | $523.85 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $516.20 | 2019-2025 | |
| Lilly USA, LLC | $330.14 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $273.20 | 2021-2025 | |
| Genzyme Corporation | $232.71 | 2019-2025 | |
| Biofrontera INC. | $214.78 | 2022 | |
| Sun Pharmaceutical Industries INC. | $197.52 | 2019-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $179.51 | 2019-2023 | Adbry |
| Vyne Pharmaceuticals INC. | $162.18 | 2020 | |
| Ucb, INC. | $157.93 | 2019-2024 | Bimzelx |
| Incyte Corporation | $152.52 | 2022-2025 | Opzelura |
| Endo Pharmaceuticals INC. | $144.24 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $134.95 | 2025 | Libtayo |
| Amgen INC. | $134.47 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $124.68 | 2025 | Puraply Wound Matrix |
| Solta Medical, A Division of Bausch Health US, LLC | $124.57 | 2025 | |
| Revance Therapeutics, INC. | $116.88 | 2024-2025 | Daxxify |
| Allergan, INC. | $97.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Merz North America, INC. | $84.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $82.40 | 2019-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $69.53 | 2019-2022 | |
| Celgene Corporation | $62.43 | 2019 | |
| Genentech USA, INC. | $55.37 | 2019 | |
| Dermavant Sciences, INC. | $41.66 | 2023 | Vtama |
| Almirall LLC | $38.97 | 2025 | Klisyri |
| Botanix Sb INC | $37.65 | 2025 | Sofdra |
| Averitas Pharma INC. | $33.31 | 2023 | Qutenza |
| Mylan Pharmaceuticals INC. | $33.25 | 2019 | |
| Journey Medical Corporation | $30.59 | 2025 | |
| Mayne Pharma Commercial LLC | $23.10 | 2019 | |
| Aclaris Therapeutics, INC. | $22.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.13 | 2024 | Sotyktu |
| Mission Pharmacal Company | $21.58 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.08 | 2025 | Zoryve |
| Musculoskeletal Transplant Foundation INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasanthi Kandula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.